Stock DNTH DIANTHUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

Real-time Estimate Cboe BZX
Other stock markets
 12:52:14 2024-05-23 pm EDT 		5-day change 1st Jan Change
21.97 USD -4.69% Intraday chart for Dianthus Therapeutics, Inc. -16.76% +121.63%
May. 16 HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target MT
May. 10 Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating MT

Evolution of the average Target Price on Dianthus Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3b895399882df049678e3ae4142b645.HhN0QyOxqmUt1P6SPL7AKeCZAh3ENNxUwNrJgM6rEnI.RkEmOmzA0A0dvozgaP2Bf6jBV0q1WOQml5yt86rOeSouSiUWG8PgVHukjQ~cc62e5840483410916e4dd188542f6ad

Analyst Recommendations on Dianthus Therapeutics, Inc.

HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target MT
Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating MT
Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating MT
Stifel Initiates Dianthus Therapeutics With Buy Rating, $44 Price Target MT
Wedbush Lifts Dianthus Therapeutics' PT to $24 From $23, Updates Estimates Following Private Placement; Keeps Outperform Rating MT
Jefferies Initiates Dianthus Therapeutics at Buy With $22 Price Target MT
Wedbush Starts Dianthus Therapeutics With Outperform Rating, $23 Price Target; Sees DNTH103 as Promising Candidate MT
Raymond James Starts Dianthus Therapeutics at Outperform, $24 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
23.05 USD
Average target price
49.29 USD
Spread / Average Target
+113.82%
High Price Target
84 USD
Spread / Highest target
+264.43%
Low Price Target
38 USD
Spread / Lowest Target
+64.86%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Dianthus Therapeutics, Inc.

HC Wainwright
Wedbush
Stifel Nicolaus
Jefferies & Co.
Raymond James

Ratings for Dianthus Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. DNTH Stock
  4. Consensus Dianthus Therapeutics, Inc.